Bedrijfsoverzicht
GlucoTrack, Inc. is a medical device company dedicated to the development and commercialization of implantable continuous blood glucose monitors specifically designed for individuals managing diabetes within the United States. The firm operates within the broader Healthcare sector, focusing on the specialized industry of Medical Instruments & Supplies, which implies a reliance on regulatory approvals and technological innovation rather than traditional consumer goods cycles. As of the latest reporting period, the company carries a market capitalization of $1.29M, though annual revenue and employee count are not disclosed in the available public data. The combination of a market cap under $1.5 million and the absence of reported revenue or employee figures indicates that GlucoTrack functions as a micro-cap entity with limited historical financial scale, suggesting the business is likely in an early-stage development or pre-commercialization phase where capital allocation is prioritized for R&D rather than established sales operations.
Financiële gezondheid
The company reports a net income loss of $-19,388,000 over the trailing twelve-month period, while EBITDA stands at $-16,048,000, revealing a significant gap between gross revenue generation and profitability that points to a cost structure heavily weighted toward research, development, and operational overhead before reaching break-even. Free cash flow is reported at $-9,444,875, which indicates that the company is consuming cash reserves to fund its operations and product development, thereby limiting its current financial flexibility to cover external obligations without raising additional capital. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure that signifies the company has not yet achieved positive profitability or that revenue is insufficient to cover variable and fixed costs, resulting in no measurable margin in the reporting period. On the balance sheet, the company holds $7.38M in cash against $3.45M in debt, creating a nominal net cash position, yet the debt-to-equity ratio of 121.85 suggests a highly leveraged capital structure relative to shareholders' equity. The current ratio stands at 1.61, indicating that for every dollar of current liabilities, the company has $1.61 in current assets, which points to a conservative stance regarding short-term liquidity despite the overall negative earnings environment. Return on Equity and Return on Assets are listed as N/A and -146.1% respectively, where the negative return on assets of -146.1% reveals that the asset base is generating value that is significantly detracting from the overall wealth of the company rather than creating it.
Waarderingsbeoordeling
Trailing P/E and forward P/E ratios are both listed as N/A because the company is currently unprofitable, which implies that traditional earnings-based valuation multiples are inapplicable and that investors must rely on alternative metrics to assess potential value. The price-to-book ratio is 0.22, indicating that the market values the company's equity at a fraction of its book value, suggesting a deep discount or high perceived risk regarding the realization of its underlying assets. Price-to-sales and EV/EBITDA ratios are N/A and 0.17 respectively, where the EV/EBITDA of 0.17 reflects an extremely low enterprise value relative to earnings before interest, taxes, depreciation, and amortization, often seen in pre-revenue biotech firms but requiring scrutiny regarding the quality of earnings and cash generation. The stock has traded between a 52-week high of $15.90 and a 52-week low of $0.62, meaning the current trading price sits significantly below the recent highs, reflecting the volatility and speculative nature typical of small-cap medical device developers. With a beta of 0.61, the stock exhibits lower volatility relative to the broader market, moving less than the S&P 500 in response to market-wide swings, which may offer some stability for risk-tolerant investors seeking exposure to niche healthcare technologies.
Growth & Income
Revenue growth and earnings growth rates are both N/A due to the lack of reported revenue and negative earnings, which prevents a direct comparison of growth trajectories but implies that the company is focused on market entry rather than expanding an existing revenue base. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that all available cash flow is retained within the business to fund operations and product development rather than being distributed to shareholders. This reinvestment strategy is typical for companies in the medical device sector that require substantial capital to navigate the lengthy regulatory approval processes necessary before generating commercial revenue. Consequently, the overall growth and income profile is characterized by a complete absence of current cash returns to investors, with all value creation dependent on the successful commercialization of the GlucoTrack device and future revenue generation.